givosiran sold brand name givlaari medication used treatment adults acute hepatic givosiran small interfering rna sirna directed towards deltaaminolevulinate synthase important enzyme production heme common side effects include nausea injection site us food drug administration fda considers firstinclass givosiran indicated treatment adults acute hepatic porphyria genetic disorder resulting buildup toxic porphyrin molecules formed production heme helps bind oxygen november givosiran approved united states treatment adults acute hepatic porphyria efficacy evaluated envision randomized multinational trial enrolling participants acute hepatic participants randomized receive monthly subcutaneous injections givosiran mgkg placebo performance givosiran measured rate porphyria attacks required hospitalizations urgent health care visits intravenous infusion hemin participants received givosiran experienced fewer porphyria attacks compared patients receiving us food drug administration fda granted application givosiran breakthrough therapy designation priority review designation orphan drug fda granted approval givlaari alnylam drug article relating blood blood forming organs stub help wikipedia expanding httpsenwikipediaorgwikigivosiran